FDA approves first treatment for ECD

Print Friendly, PDF & Email


Micrograph showing ECD
Image from Wikipedia
The US Food and Drug Administration (FDA) has expanded the approved use of vemurafenib (Zelboraf) to include the treatment of adults who have Erdheim-Chester disease (ECD) with BRAF V600 mutation. Vemurafenib is a kinase inhibitor designed to inhibit some mutated forms of BRAF. The drug was already approved... [Read Article]
Print Friendly, PDF & Email

NCCN releases new guidelines for patients with MPNs

Print Friendly, PDF & Email


Polycythemia vera
Image courtesy of AFIP
The National Comprehensive Cancer Network® (NCCN) has released new guidelines for patients with myeloproliferative neoplasms (MPNs). The guidelines include information on the diagnosis and treatment of polycythemia vera, essential thrombocythemia, and myelofibrosis. NCCN Guidelines for Patients® are written in plain language and include tools such as suggested questions... [Read Article]
Print Friendly, PDF & Email

JAK inhibitors face off in myelofibrosis trial

Print Friendly, PDF & Email


Micrograph showing MF
Results of the SIMPLIFY-1 study revealed how 2 JAK inhibitors—momelotinib and ruxolitinib—compared to one another in myelofibrosis (MF) patients who were previously JAK-inhibitor-naïve. Momelotinib proved noninferior to ruxolitinib when it came to spleen reduction but not symptom response. On the other hand, momelotinib was more effective than ruxolitinib in reducing... [Read Article]
Print Friendly, PDF & Email

Methotrexate could treat myeloproliferative neoplasms

Print Friendly, PDF & Email


Micrograph showing PV
Image courtesy of AFIP
Methotrexate (MTX) may be a feasible treatment option for myeloproliferative neoplasms (MPNs), according to preclinical research published in Haematologica. Researchers tested low-dose MTX in mouse models that mimic human MPNs—essential thrombocythemia (ET) and polycythemia vera (PV). The team found that MTX inhibited the JAK/STAT pathway, normalized... [Read Article]
Print Friendly, PDF & Email

Drug granted priority review, breakthrough designation for ECD

Print Friendly, PDF & Email


Erdheim–Chester disease
Image from Wikimedia
The US Food and Drug Administration (FDA) has granted priority review and breakthrough therapy designation to vemurafenib (Zelboraf®) as a treatment for Erdheim-Chester disease (ECD) with BRAF V600 mutation. Vemurafenib is a kinase inhibitor designed to inhibit some mutated forms of BRAF. The drug is already FDA-approved to... [Read Article]
Print Friendly, PDF & Email

Long-term maintenance deemed feasible in PV

Print Friendly, PDF & Email


Micrograph showing PV
Image courtesy of AFIP
Long-term maintenance with ropeginterferon alfa-2b is feasible, effective, and well-tolerated in patients with polycythemia vera (PV), according to researchers. In the ongoing phase 1/2 PEGINVERA study, patients have received ropeginterferon alfa-2b for a median of 4 years. After the first 2 years, patients switched from bi-weekly... [Read Article]
Print Friendly, PDF & Email

FDA clears use of reagents to detect hematopoietic neoplasia

Print Friendly, PDF & Email


Blood samples
Photo by Graham Colm
The US Food and Drug Administration (FDA) has allowed marketing of the ClearLLab Reagent Panel, a combination of conjugated antibody cocktails designed to aid the detection of hematopoietic neoplasia. This includes chronic and acute leukemias, non-Hodgkin lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. The ClearLLab reagents are... [Read Article]
Print Friendly, PDF & Email

Patients with thrombocytosis should be tested for cancers, team says

Print Friendly, PDF & Email


Platelets (blue) surrounded
by red blood cells
Image by Graham Beards
Researchers have found evidence to suggest that thrombocytosis is a strong predictor of cancer, particularly lung and colorectal cancer. The team therefore believes patients with thrombocytosis should be evaluated for an underlying malignancy, as such investigation could speed up cancer diagnosis and... [Read Article]
Print Friendly, PDF & Email

Role of TET2 in hematologic malignancies

Print Friendly, PDF & Email


Tumor-cell infiltration
into the liver of a
Tet2-knockout mouse.
Image from Sylvester
Comprehensive Cancer Center
New research appears to explain how TET2 mutations increase the risk of hematologic malignancies. In studying mouse models and patient samples, researchers found evidence to suggest that loss of TET2 opens the door for mutations that drive lymphoid... [Read Article]
Print Friendly, PDF & Email